Follicular Lymphoma International Prognostic Index (FLIPI)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–1
- Intermediate Risk2–2
- High Risk3–5
The Follicular Lymphoma International Prognostic Index (FLIPI) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include age over 60. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Estimates overall survival in patients with follicular lymphoma based on 5 adverse prognostic factors to stratify patients into risk groups for treatment planning.
Clinical Indication
The Follicular Lymphoma International Prognostic Index (FLIPI) is indicated for bedside clinical practice to support Estimates overall survival in patients with follicular lymphoma based on 5 adverse prognostic factors to stratify patients into risk groups for treatment planning.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
Sum of adverse prognostic factors (1 point each): Age >60 years + >4 nodal sites + Elevated LDH + Hemoglobin <120 g/L + Stage III-IV
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age_over_60 | string | Yes | Patient age greater than 60 years |
| nodal_sites_over_4 | string | Yes | More than 4 nodal sites involved |
| ldh_elevated | string | Yes | Serum LDH level above normal |
| hemoglobin_below_120 | string | Yes | Hemoglobin level below 120 g/L (12 g/dL) |
| stage_3_or_4 | string | Yes | Ann Arbor stage III or IV disease |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Low Risk | 0-1 adverse factors |
| 2–2 | Intermediate Risk | 2 adverse factors |
| 3–5 | High Risk | 3-5 adverse factors |
Evidence-Based References (EBM)
- Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1;104(5):1258-65.
- van de Schans SA, Steyerberg EW, Nijziel MR, Creemers GJ, Janssen-Heijnen ML, van Spronsen DJ. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol. 2009 Oct;20(10):1697-702.
- Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009 Sep 20;27(27):4555-62.
Related calculators
- EUTOS Score for Chronic Myelogenous Leukemia (CML)
- Binet Staging System for Chronic Lymphocytic Leukemia (CLL)
- International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)
- International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)
- Mantle Cell Lymphoma International Prognostic Index (MIPI)